Summit Therapeutics secures $62m contract to develop ridinilazole for CDI treatment

UK-based drug discovery and development company Summit Therapeutics has secured a contract worth up to $62m to support the clinical and regulatory development of ridinilazole for the treatment of C. difficile infection (CDI).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news